MENU

ARTL Artelo Biosciences Forecast, Technical & Fundamental Analysis

a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system.

Industry Biotechnology
ARTL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
ARTL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ARTL is expected to report earnings to -77 cents per share on August 07

Artelo Biosciences ARTL Stock Earnings Reports
Q2'24
Est.
$-0.77
Q1'24
Beat
by $0.13
Q4'23
Missed
by $0.43
Q3'23
Missed
by $0.18
Q2'23
Beat
by $0.21
The last earnings report on May 13 showed earnings per share of -77 cents, beating the estimate of -91 cents. With 1.67K shares outstanding, the current market capitalization sits at 4.49M.
A.I. Advisor
published General Information

General Information

a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
505 Lomas Santa Fe
Phone
+1 858 925-7049
Employees
6
Web
https://www.artelobio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LNZA2.130.17
+8.67%
LanzaTech Global
COYA7.390.30
+4.23%
Coya Therapeutics
RCKT25.880.85
+3.40%
Rocket Pharmaceuticals
THC149.744.40
+3.03%
Tenet Healthcare Corp
TRVN0.23N/A
+2.13%
Trevena

ARTL and Stocks

Correlation & Price change

A.I.dvisor tells us that ARTL and CRMD have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ARTL and CRMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARTL
1D Price
Change %
ARTL100%
+0.72%
CRMD - ARTL
32%
Poorly correlated
-1.47%
FATE - ARTL
31%
Poorly correlated
+4.25%
MDGL - ARTL
29%
Poorly correlated
+0.47%
VTYX - ARTL
28%
Poorly correlated
+2.46%
TRVN - ARTL
28%
Poorly correlated
+2.13%
More